Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immune cell 'Fitness' may predict success of advanced myeloma therapies in older patients

NCT ID NCT07674498

Knowledge-focused Sponsor: Jules Bordet Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study investigates whether the health of a patient's immune cells can predict how well they will respond to CAR-T or bispecific antibody treatments for relapsed multiple myeloma. Researchers will analyze blood samples from patients aged 65 and older before they start standard therapy, looking at markers of immune cell aging and exhaustion. The goal is to combine immune profiles with frailty assessments to better personalize treatment for older adults.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could help doctors predict which older patients will benefit most from advanced immunotherapies, leading to more personalized treatment plans.
What could go wrong
This is an observational study, not a treatment trial. It aims to gather information, not test a new therapy, so it will not directly improve outcomes for participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 31 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥ 65 years old * Relapsed/refractory multiple myeloma * Eligible for a CAR-T cell or bispecific antibody therapies Exclusion Criteria: * \<65 years old * Active cancer other than myeloma * Active AL amyloidosis * Central nervous system (CNS) involvement

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myeloma multiple are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myeloma multiple

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Saint-Pierre

    NOT_YET_RECRUITING

    Brussels, Brussels Capital, 1000, Belgium

  • Institut Jules Bordet

    RECRUITING

    Anderlecht, Brussels Capital, 1070, Belgium

  • institut roi albert II

    NOT_YET_RECRUITING

    Woluwe-Saint-Lambert, Brussels Capital, 1200, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.